Skip to main content

Dihexa vs DSIP

Both Dihexa and DSIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

Dihexa

Evidence C

Dihexa (PNB-0408)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

View full Dihexa profile →

DSIP

Evidence C

Delta Sleep-Inducing Peptide

A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.

View full DSIP profile →

Side-by-Side

AttributeDihexaDSIP
Evidence GradeCC
FDA StatusNot FDA-approved — research compound (HGF/c-Met-mimetic)Not FDA-approved — research compound
Typical Dose8–45 mg orally daily (research-only)100–300 mcg before bed (subcutaneous)
Clinics Indexed1038
Categoriescognitive, neuroprotectionsleep, neuroprotection

Key reported benefits — Dihexa

  • Synaptogenesis (preclinical)
  • Memory improvement (animal)
  • Possible Alzheimer's relevance

Key reported benefits — DSIP

  • Slow-wave-sleep signals (preclinical)
  • Stress/cortisol modulation
  • Possible analgesic effect

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons